Evidence map›Paper›PMID 35118791›Full record

ArticleJournal of cellular and molecular medicine2022

Regulation of total LC3 levels by angiotensin II in vascular smooth muscle cells.

David Mondaca-Ruff, Clara Quiroga, Ignacio Norambuena-Soto, Jaime A Riquelme, Alejandra San Martin, Mario Bustamante, Sergio Lavandero, Mario Chiong

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

David Mondaca-RuffAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0001-9211-2963
Clara QuirogaAdvanced Center for Chronic Diseases (ACCDiS), Facultad Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-0251-4772
Ignacio Norambuena-SotoAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-2676-2674
Jaime A RiquelmeAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0003-0517-5697
Alejandra San MartinDivision of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-4620-1591
Mario BustamanteAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-0713-1818
Sergio LavanderoAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0003-4258-1483
Mario ChiongAdvanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-5174-6545
Advanced Center for Chronic Diseases · CLPontificia Universidad Católica de Chile · CLEmory University · US

Funding

T cell triggering events and hypertensionP01HL095070 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2009 to 2019
$20.5M
Mechanically Stressed VSMC: A Role for Slingshot Phosphatase in InflammationR01HL113167 · NHLBI · EMORY UNIVERSITY · PI SAN MARTIN, ALEJANDRA · 2013 to 2017
$1.9M
NHLBI NIH HHS R01 HL113167NIH HHS HL095070NIH HHS HL113167
6 · The paper itself

Abstract

Hypertension is associated with high circulating angiotensin II (Ang II). We have reported that autophagy regulates Ang II-induced vascular smooth muscle cell (VSMC) hypertrophy, but the mechanism mediating this effect is still unknown. Therefore, we studied how Ang II regulates LC3 levels in VSMCs and whether Bag3, a co-chaperone known to regulate LC3 total levels, may be involved in the effects elicited by Ang II. A7r5 cell line or rat aortic smooth muscle cell (RASMC) primary culture were stimulated with Ang II 100 nM for 24 h and LC3 I, LC3 II and Bag3 protein levels were determined by Western blot. MAP1LC3B mRNA levels were assessed by RT-qPCR. Ang II increased MAP1LC3B mRNA levels and protein levels of LC3 I, LC3 II and total LC3 (LC3 I + LC3 II). Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs. In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II. Moreover, Ang II increased Bag3 levels, but this increase was not observed upon co-administration with either losartan 1 μM (AT1R antagonist) or Y-27632 10 μM (ROCK inhibitor). These results suggest that Ang II may regulate total LC3 content through transcriptional and translational mechanisms. Moreover, Bag3 is increased in response to Ang II by a AT1R/ROCK signalling pathway. These data provide preliminary evidence suggesting that Ang II may stimulate autophagy in VSMCs by increasing total LC3 content and LC3 processing.

Indexed as

Angiotensin IIMuscle, Smooth, VascularAdaptor Proteins, Signal TransducingAnimalsApoptosis Regulatory ProteinsCells, CulturedCycloheximideMicrotubule-Associated ProteinsMyocytes, Smooth MuscleRatsRNA, MessengerAdaptor Proteins, Signal TransducingAngiotensin IIAnxa3 protein, ratApoptosis Regulatory ProteinsBAG3 protein, ratCycloheximideMicrotubule-Associated ProteinsRNA, Messengerangiotensin IIAT1 receptorautophagyBag3LC3ROCK

Identifiers

PMID35118791
PMCPMC8899170
OpenAlexW4210645467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.